Skip to main
CAMP

CAMP Stock Forecast & Price Target

CAMP Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Camp4 Therapeutics is in a strong financial position with a cash balance of $133 million, giving them ample resources to fund operations through YE:28. Their lead asset, CMP-002, has shown promising preclinical data in restoring protein levels and improving symptoms in a SYNGAP1 mouse model. With no competing therapies currently in clinical trials, Camp4 is poised to be first to market for this indication, making their novel regRNA-targeting strategy potentially lucrative.

Bears say

Camp4 Therapeutics is a clinical-stage biopharmaceutical company with a negative outlook due to competition in the intensely competitive biotechnology and pharmaceutical industries and the need for additional funding for its research and development programs, regulatory processes, and future sales and marketing infrastructure. Additionally, the company's ASO optimization is based on empirical data, which may not accurately reflect the mechanism of action of its regRNA programs. Furthermore, there is a risk that regulatory authorities may not approve the company's products for the requested indications, which could negatively impact its stock price.

CAMP has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CAMP4 Therapeutics Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CAMP4 Therapeutics Corp (CAMP) Forecast

Analysts have given CAMP a Buy based on their latest research and market trends.

According to 6 analysts, CAMP has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CAMP4 Therapeutics Corp (CAMP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.